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a scale of 0 to 100. Signiﬁcative difference was observed
between M and W for the global handicap score 20.73
vs 16,95 p < 0,002. Two groups were identiﬁed: ﬂare-up
of psoriasis (84%), psoriasis not in ﬂare-up (12%)—no
answers (4%)- Psoriasis had a greater affect on patients
with episode: PDI score = 20,24 (sd 17,52) than the
patient without episode PDI score = 8.98 (sd 11,34). This
difference was signiﬁcant p < 0.00001. CONCLUSION:
These results highlight the value of appropriate and rele-
vant psychological and medical environment for patient
suffering from psoriasis.
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PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE
SYMPTOMATOLOGY: FRENCH RESULTS
Taïeb C1, Corvest M2, Myon E1
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OBJECTIVE: To evaluate the effect of psoriasis on
quality of life of patients and DS in France. To highlight
a relation between DS and quality of life for patients suf-
fering from psoriasis. METHOD: Seven hundred ﬁfty
anonymous questionnaires (comprised two scales: the
Psoriasis Disability Index [PDI] and the Center for Epi-
demiologic Studies—Depression scale [CES-D] were sent,
via a Psoriasis Patient Support Group (APLCP). The CES-
D, a short self-report scale composed of 20 items is a
questionnaire designed to measure DS in the general pop-
ulation. The CES-D is widely used in epidemiological
surveys on large populations. The PDI is a questionnaire
speciﬁc for psoriasis patients. RESULTS: 297 question-
naires were returned (June 2002): response rate 39.6%.
The sex ratio Men (M)/Women (W) was 47/53. Mean
age: 48.8 years. Mean age of diagnosis: 26.3 years. The
average to the total PDI score was 10.3 (s.d: 7.7 rank 0
to 39) i.e 22.8 (sd: 17.10) when reported to a scale of 0
to 100. Signiﬁcant difference was observed between W
and M for the global handicap score 24.53 vs 19.87 p <
0.02. Two groups were identiﬁed: ﬂare-up of psoriasis
(49.5%), psoriasis not in ﬂare-up (48%)—no answers
(2.5%)—Psoriasis had a greater affect on patients with
episode: PDI score = 24.9 (s.d: 17.02) than patient
without episode: PDI score = 20.27 (s.d: 16.91). This dif-
ference was signiﬁcant (p < 0.05). In the studied popula-
tion, 44.6% of the patients reported DS (CES-D+)
whereas 55.4% did not (CES-D-). In CES-D+ patients the
PDI score = 30.98 (sd: 18.28) was higher than the score
in CES-D-patients: PDI score = 16.43 (sd: 13.97). This
difference was signiﬁcant (p < 2.10–11). CONCLUSION:
Patients in a current ﬂare-up of psoriasis are more
affected and feel more disabled in their daily life (higher
disability score and higher frequency of DS) compared to
patients without episode. Patients with DS (CES-D+),
reported a higher impact of their psoriasis on their quality
of life (PDI score 30.98 versus 16.43).
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ASSESSMENT OF THE DERMATOLOGIC LIFE
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IDIOPATHIC URTICARIA
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The Dermatology Life Quality Index (DLQI) was
designed to be used with different types of dermatologic
pathologies instead of being directed at a single condi-
tion such as psoriasis or acne. Although a reasonable
approach, this broader measurement model may not be
appropriate for conditions such as chronic idiopathic
urticaria (CIU) that, unlike some other chronic skin con-
ditions, are subject to daily or weekly ﬂuctuations.
OBJECTIVES: This validation study tested the reliability,
structural validity, and construct validity of the DLQI in
two samples of CIU patients obtained from two large
identical multicenter, double-blind, randomized, placebo-
controlled, parallel studies. METHODS: Patients
recorded daily signs and symptoms (# of wheals and 
pruritus severity) on a daily basis, and completed the
DLQI during three clinic visits (approximately 2 weeks
apart); investigators also assessed CIU severity.
RESULTS: The DLQI means and standard deviations
indicated relatively symmetrical distributions free from
serious ceiling or ﬂoor effects, and alpha coefﬁcients indi-
cated an acceptable level of reliability in the two samples.
The exploratory factor analysis suggested that the six cat-
egories of items did not deﬁne different factors and sup-
ported the unidimensionality of the scale. In a formal test
of the structural validity for a single-factor model, con-
ﬁrmatory factor analysis supported either a one or two-
factor model, with the correlations from the two-factor
model indicating that the total score of all items is inter-
pretable as a global score. Item response analyses showed
that most items were able to distinguish people with 
low versus high impairment at the appropriate ends of 
the continuum demonstrating content validity. Finally,
changes in DLQI scores were related to changes in inves-
tigator and patient-assessed symptoms of urticaria, pro-
viding evidence of construct validity. CONCLUSION:
These results support the DLQI as a valid instrument for
the measurement of CIU related quality of life.
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OBJECTIVES: In spite of the common occurrence of der-
matological problems there are virtually no population-
based studies on the impact of skin diseases in the
561Abstracts
population. The aim of the study was to evaluate the
impact of skin diseases on health state utlilities in the 
population. METHODS: A postal survey was carried out
on a sample of the population 20–84 years of age (n =
8000) of the county of Uppland, Sweden. Information on
dermatological problems was obtained by self-report.
Rating Scale was used to measure health state utilities.
RESULTS: The response rate was 68% (5404 individu-
als). A large proportion (20.5%) reported dermatological
problems and/or use of topical dermatological drugs. Skin
disease was evenly distributed over age but was more fre-
quent among women (23.3%) than among men (17.3%).
Persons reporting dermatological problems also reported
lower health state utility than others, 0.807 as compared
to 0.836 (p < 0.001). Dermatological problems had an
independent and statistically signiﬁcant (p < 0.01) effect
on utility when age, gender, somatic and psychiatric
comorbidity were included in a multivariate analysis.
CONCLUSIONS: The study shows that skin disorders
are a considerable problem in the population, and that
they do cause a decrease in health state utility as mea-
sured by the Rating Scale (RS). The result of this study
emphasizes the need for further epidemiological studies
analysing health state utilities in relation to severity and
type of skin disease.
INFECTION—Economic Outcomes
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THE COSTS OF SEVERE SEPSIS—THE
NETHERLANDS, 2000
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OBJECTIVES: New therapies for the treatment of severe
sepsis are in development and estimates are required 
of treatment costs, annual incidence and the national
burden-of-illness. This study concerns the Netherlands.
METHODS: Cost data were collected for 100 patients
consecutively admitted to a general hospital ICU from
1998 to 2000 for treatment of a ﬁrst episode of severe
sepsis. Costs were limited to direct medical ICU costs
from a societal perspective and collected with an activity
based information system. Annual incidence was esti-
mated with a point-prevalence survey in Dutch ICU’s, col-
lecting the clinical information concerning all patients at
the ICU on a single day. Patients were regarded as severely
septic if infection was present, two or more SIRS criteria
were fulﬁlled and when there was at least one dysfunc-
tional organ system. RESULTS: Daily costs were esti-
mated to be log-normally distributed with a mean of
€1,244 ± 404. ICU length of stay was estimated to be geo-
metrically distributed with a mean of 15.3 ± 15.8 days.
Total treatment costs were estimated at €19,509 ± 26,966
(log-normal). Main cost items were ﬁxed costs (43%),
nursing costs (28%), diagnostic tests (7%), medication
(5%), renal replacement therapy (5%) and blood (4%).
The presence of shock and/or renal failure was signiﬁ-
cantly associated with higher treatment costs, whereas
ICU survival only showed a trend towards increase.
Forty-seven ICU’s participated in the prevalence survey
and 143 patients were found to meet the criteria for
severe sepsis. The national incidence was estimated at
8,643 ± 929 patients per year. CONCLUSIONS: Costs of
severe sepsis treatment within the ICU are estimated at
€168.6 ± €29.5 million per year. This equals 1.7% of the
national hospital budget and 0.51% of all healthcare
expenses in 2000 in the Netherlands.
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OBJECTIVES: To determine and compare costs and cost
driving factors in the management of severe sepsis either
within a clinical trial setting or in daily practice.
METHODS: One hundred ﬁfty-two patients (from 4
Belgian centres) fulﬁlling criteria for severe sepsis between
1998 and 2000 were included in a chart review. Ninety-
one were clinical trial patients (rhAPC, TFPI or ATIII);
61 were non-trial patients. All healthcare costs (payers
perspective) between sepsis diagnosis and discharge were
collected from patient invoices by independent
researchers. RESULTS: Trial and non-trial patients were
comparable with regard to age, status (medical or surgi-
cal), underlying conditions including COPD, alcohol or
tobacco abuse and immunosuppression. Differences were
observed in mortality (45% versus 50%, trial versus non-
trial patients respectively), positive blood cultures (39%
versus 75%), renal replacement therapy (22% versus
31%), hypertension (41% versus 31%) cardiomyopathy
(16% versus 29%) cerebrovascular disease (5% versus
13%) and malignancy (19.8% versus 8%). There was no
difference (trial versus non-trial) in hospital (28 versus 27
days) or ICU length of stay (16 days both) after sepsis
diagnosis. Overall costs were similar in trial and non-trial
patients: €19,292 (St E:1,574) versus €16,314 (St E:
1,684) respectively. Multivariate regression (OLS on log-
transformed cost) revealed the following explaining
factors for total cost: death (neg. p = 0.003), pos. blood
culture (pos. p = 0.009), university hospital (pos. p =
0.035), mechanical ventilation (pos. p = 0.002) and renal
replacement therapy (pos. p = 0.002). The variable “trial
patient or not” revealed a p-value of 0.624. CONCLU-
SIONS: Factors inﬂuencing costs in severe sepsis include
death, pos. blood culture, university hospital setting,
renal replacement therapy and ventilation. Trial and non-
trial patients appear to be comparable with regard to
